Immunic Historical Income Statement

IMUX Stock

USD 1.11 0.00 0.00%

Historical analysis of Immunic income statement accounts such as Other Operating Expenses of 54.8 M or Research Development of 87.4 M can show how well Immunic performed in making a profits. Evaluating Immunic income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Immunic's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Immunic latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunic is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

About Immunic Income Statement Analysis

Immunic Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Immunic shareholders. The income statement also shows Immunic investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Immunic Income Statement Chart

At this time, Immunic's Research Development is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 5.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 105.5 K in 2024.

Operating Income Ebit Minority Interest

Operating Income

Operating Income is the amount of profit realized from Immunic operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Immunic is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Minority Interest

Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Immunic whose combined shares represent less than 50% of the total outstanding shares issued by Immunic have a minority interest in Immunic.

Most accounts from Immunic's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.At this time, Immunic's Research Development is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 5.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 105.5 K in 2024.

	2021	2022	2023	2024 (projected)
Net Interest Income	66K	1.0M	3.1M	3.2M
Interest Income	66K	1.0M	3.1M	3.2M

Net Interest Income Interest Income

Immunic income statement Correlations

	Depreciation And Amortization	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Gross Profit	Cost Of Revenue	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.16	-0.47	0.53	0.53	-0.5	0.54	-0.47	0.51	-0.02	0.5	-0.5	-0.51	0.55	0.12	-0.42	-0.38	0.8	-0.79	0.89	0.38
Interest Expense	0.16		-0.5	0.45	0.44	-0.43	0.43	-0.5	0.46	0.83	0.4	0.13	-0.41	0.11	0.27	-0.13	-0.09	0.27	-0.26	0.28	0.08
Other Operating Expenses	-0.47	-0.5		-0.94	-0.93	0.89	-0.93	1.0	-0.94	-0.42	-0.89	0.47	0.78	-0.75	-0.69	0.51	0.46	-0.74	0.8	-0.65	-0.3
Operating Income	0.53	0.45	-0.94		1.0	-0.96	1.0	-0.94	1.0	0.35	0.98	-0.66	-0.8	0.88	0.74	-0.65	-0.6	0.82	-0.8	0.71	0.48
Ebit	0.53	0.44	-0.93	1.0		-0.96	1.0	-0.93	1.0	0.33	0.98	-0.67	-0.79	0.89	0.73	-0.64	-0.6	0.81	-0.79	0.71	0.48
Research Development	-0.5	-0.43	0.89	-0.96	-0.96		-0.96	0.89	-0.94	-0.22	-0.89	0.72	0.76	-0.84	-0.7	0.79	0.76	-0.83	0.76	-0.68	-0.68
Ebitda	0.54	0.43	-0.93	1.0	1.0	-0.96		-0.93	1.0	0.33	0.98	-0.67	-0.79	0.89	0.72	-0.64	-0.6	0.81	-0.79	0.71	0.48
Total Operating Expenses	-0.47	-0.5	1.0	-0.94	-0.93	0.89	-0.93		-0.94	-0.42	-0.89	0.47	0.78	-0.75	-0.69	0.51	0.46	-0.74	0.8	-0.65	-0.3
Income Before Tax	0.51	0.46	-0.94	1.0	1.0	-0.94	1.0	-0.94		0.4	0.98	-0.63	-0.8	0.88	0.75	-0.61	-0.56	0.8	-0.78	0.68	0.44
Total Other Income Expense Net	-0.02	0.83	-0.42	0.35	0.33	-0.22	0.33	-0.42	0.4		0.39	0.29	-0.36	0.08	0.39	0.14	0.19	0.11	-0.17	0.07	-0.25
Net Income	0.5	0.4	-0.89	0.98	0.98	-0.89	0.98	-0.89	0.98	0.39		-0.64	-0.77	0.89	0.72	-0.55	-0.51	0.75	-0.75	0.66	0.36
Income Tax Expense	-0.5	0.13	0.47	-0.66	-0.67	0.72	-0.67	0.47	-0.63	0.29	-0.64		0.57	-0.81	-0.51	0.89	0.89	-0.72	0.63	-0.53	-0.77
Selling General Administrative	-0.51	-0.41	0.78	-0.8	-0.79	0.76	-0.79	0.78	-0.8	-0.36	-0.77	0.57		-0.63	-0.76	0.64	0.59	-0.81	0.81	-0.67	-0.42
Net Income From Continuing Ops	0.55	0.11	-0.75	0.88	0.89	-0.84	0.89	-0.75	0.88	0.08	0.89	-0.81	-0.63		0.71	-0.65	-0.64	0.76	-0.73	0.6	0.52
Non Operating Income Net Other	0.12	0.27	-0.69	0.74	0.73	-0.7	0.72	-0.69	0.75	0.39	0.72	-0.51	-0.76	0.71		-0.56	-0.53	0.6	-0.57	0.3	0.42
Interest Income	-0.42	-0.13	0.51	-0.65	-0.64	0.79	-0.64	0.51	-0.61	0.14	-0.55	0.89	0.64	-0.65	-0.56		0.99	-0.75	0.62	-0.48	-0.92
Net Interest Income	-0.38	-0.09	0.46	-0.6	-0.6	0.76	-0.6	0.46	-0.56	0.19	-0.51	0.89	0.59	-0.64	-0.53	0.99		-0.7	0.57	-0.43	-0.92
Gross Profit	0.8	0.27	-0.74	0.82	0.81	-0.83	0.81	-0.74	0.8	0.11	0.75	-0.72	-0.81	0.76	0.6	-0.75	-0.7		-0.96	0.89	0.64
Cost Of Revenue	-0.79	-0.26	0.8	-0.8	-0.79	0.76	-0.79	0.8	-0.78	-0.17	-0.75	0.63	0.81	-0.73	-0.57	0.62	0.57	-0.96		-0.88	-0.44
Reconciled Depreciation	0.89	0.28	-0.65	0.71	0.71	-0.68	0.71	-0.65	0.68	0.07	0.66	-0.53	-0.67	0.6	0.3	-0.48	-0.43	0.89	-0.88		0.42
Selling And Marketing Expenses	0.38	0.08	-0.3	0.48	0.48	-0.68	0.48	-0.3	0.44	-0.25	0.36	-0.77	-0.42	0.52	0.42	-0.92	-0.92	0.64	-0.44	0.42

Click cells to compare fundamentals

Immunic Account Relationship Matchups

Immunic income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	50K	39K	85K	77K	111K	105.5K
Interest Expense	107K	58K	85K	1.0M	936.9K	730.2K
Other Operating Expenses	37.0M	49.0M	91.7M	86.5M	99.2M	54.8M
Operating Income	(37.0M)	(49.0M)	(91.7M)	(119.5M)	(99.2M)	(94.3M)
Ebit	(37.0M)	(49.0M)	(91.7M)	(120.4M)	(99.2M)	(94.3M)
Research Development	22.5M	38.6M	61.1M	71.3M	83.2M	87.4M
Ebitda	(37.0M)	(48.9M)	(91.6M)	(120.3M)	(99.1M)	(94.2M)
Total Operating Expenses	37.0M	49.0M	91.7M	86.5M	99.2M	54.8M
Income Before Tax	(34.9M)	(44.0M)	(92.9M)	(120.4M)	(93.6M)	(88.9M)
Total Other Income Expense Net	2.1M	5.0M	(1.3M)	(919K)	5.6M	5.9M
Net Income	(34.8M)	(44.0M)	(92.8M)	(154.3M)	(93.6M)	(88.9M)
Income Tax Expense	(107K)	(58K)	(151K)	33.9M	39.0M	40.9M
Selling General Administrative	14.5M	10.3M	13.3M	15.3M	16.0M	14.0M
Net Income From Continuing Ops	(34.9M)	(44.0M)	(92.9M)	(120.4M)	(93.6M)	(98.3M)
Non Operating Income Net Other	2.1M	5.0M	(1.3M)	(919K)	(827.1K)	(785.7K)
Net Income Applicable To Common Shares	(34.9M)	(44.0M)	(92.9M)	(120.4M)	(108.4M)	(102.9M)
Net Interest Income	107K	58K	66K	1.0M	3.1M	3.2M
Reconciled Depreciation	50K	39K	85K	77K	111K	105.5K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunic Historical Income Statement

About Immunic Income Statement Analysis

Immunic Income Statement Chart

Operating Income

Minority Interest

Immunic income statement Correlations

Immunic Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunic income statement Accounts

Also Currently Popular

Additional Tools for Immunic Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit

Cost Of Revenue	- 0.96	Gross Profit
Ebitda	- 0.96	Research Development
Research Development	- 0.96	Ebit
Research Development	- 0.96	Operating Income
Income Before Tax	- 0.94	Total Operating Expenses
Income Before Tax	- 0.94	Research Development